Search

Your search keyword '"Lee, Woo Sik"' showing total 596 results
Start Over Author "Lee, Woo Sik"
596 results on '"Lee, Woo Sik"'

3. Predictive model of IVF outcomes for polycystic ovarian morphology and polycystic ovary syndrome in GnRH antagonist protocol using AMH‐MoM and ovarian sensitivity index.

Author

Ko, Yoo Ra, Yu, Eun Jeong, Park, Jae Eun, Park, Jae Kyun, Eum, Jin Hee, Kim, Tae Hyung, Lee, Woo Sik, and Lee, Hee Jun

Subjects
POLYCYSTIC ovary syndrome treatment, OVARIAN hyperstimulation syndrome, SEX hormones, OVUM, PREDICTION models, RESEARCH funding, BODY mass index, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, FERTILIZATION in vitro, GONADOTROPIN releasing hormone, OVARIAN reserve, COMPARATIVE studies, CONFIDENCE intervals, ABORTION, CHEMICAL inhibitors
Abstract

Aim: To evaluate the relationship between AMH and ovarian response to controlled ovarian hyperstimulation in women with PCOM and PCOS. Methods: A retrospective study was conducted on 559 patients who underwent the IVF‐ET cycle between January 2018 and December 2022 at Gangnam Cha Hospital. Patients were divided into 3 groups matched for age and BMI: the PCOS group (n = 54), based on the new 2023 PCOS guideline; the PCOM group (n = 53); and the control group (n = 452) with normal ovaries. Serum AMH levels were converted to multiples of the median (MoM) for each corresponding age. The ovarian sensitivity index (OSI) was calculated as the number of retrieved oocytes divided by the total dose of recombinant FSH administered (per 1000 IU). Results: There were significant differences in AMH‐MoM value among women with PCOS [2.7 ± 1.3 (95% CI 2.3–3.0)], those with PCOM [2.0 ± 1.0 (95% CI 1.7–2.3)], and controls [0.8 ± 0.7 (95% CI 0.8–0.9)] (p < 0.001). The abortion rates in the normoovulatory, PCOM, and PCOS groups were 18.2%, 21.1%, and 25.0%, respectively. OSI and live birth rate were positively correlated with the AMH‐MoM value in normoovulatory women (r = 0.389, p < 0.05, r = 0.122, p < 0.05), while no such correlation was observed in women with PCOM and PCOS. Conclusions: Ovarian response and live birth rate are possibly correlated with the AMH‐MoM value in normoovulatory women, but not in women with PCOM and PCOS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. COVID-19 (SARS-CoV-2) mRNA vaccination does not affect basal sex hormone levels (follicle-stimulating hormone, luteinizing hormone, estradiol) in reproductive-age women.

Author

Jeon, Haeng Jun, Lee, Woo Sik, Park, Ji Eun, Hwang, Ji Young, and Kim, Ji Won

Subjects
*SARS-CoV-2, *SEX hormones, *VACCINATION complications, *FOLLICLE-stimulating hormone, *COVID-19
Abstract

Objective: People vaccinated with the coronavirus disease 2019 (COVID-19) (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) mRNA vaccine have reported experiencing various adverse effects. For instance, reproductive-age women have presented with complaints of abnormal uterine bleeding or menstrual cycle changes. We speculated that differences in basal sex hormone levels before and after vaccination may be present in women who experienced irregular bleeding or menstrual cycle changes; thus, this study aimed to investigate the differences in basal sex hormone levels of women before and after two doses of SARS-CoV-2 mRNA vaccination. Methods: This retrospective study included patients who received SARS-CoV-2 mRNA vaccines between January 2021 and February 2022 at a single center. In an outpatient setting, patients were queried regarding their menstrual cycle, the date of SARS-CoV-2 mRNA vaccination, vaccination type, and vaccination side effects. Differences in basal hormone levels (menstrual cycle days 2–3, follicle-stimulating hormone [FSH], luteinizing hormone [LH], and estradiol) before and after vaccination were compared. Results: Among the 326 patients, patients with no laboratory records of the hormones were excluded. The median time interval between SARS-CoV-2 mRNA vaccination and the laboratory test day was 79 days (interquartile range, 44 to 127). A comparative analysis of these hormones before and after vaccination revealed no significant differences. Subgroup analyses based on age and reported adverse events also found no statistically significant differences. Conclusion: This study showed no significant differences in basal hormone levels (FSH, LH, and estradiol) before and after SARS-CoV-2 mRNA vaccination. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Clinical Usability of Embryo Development Using a Combined Qualitative and Quantitative Approach in a Single Vitrified-Warmed Blastocyst Transfer: Assessment of Pre-Vitrified Blastocyst Diameter and Post-Warmed Blastocyst Re-Expansion Speed

Author

Park, Jae Kyun, primary, Ahn, So-Yeon, additional, Seok, Su Hee, additional, Park, Sol Yi, additional, Bang, Soyoung, additional, Eum, Jin Hee, additional, Kwak, In Pyung, additional, Kim, Ji Won, additional, and Lee, Woo Sik, additional

Published
2022
Full Text
View/download PDF

48. Effect of a dual trigger on oocyte maturation in young women with decreased ovarian reserve for the purpose of elective oocyte cryopreservation

Author

Kim, Se Jeong, Kim, Tae Hyung, Park, Jae Kyun, Eum, Jin Hee, Lee, Woo Sik, and Lyu, Sang Woo

Subjects
0301 basic medicine, Agonist, Oocyte, endocrine system, medicine.drug_class, Dual trigger, Cryopreservation, Human chorionic gonadotropin, Andrology, 03 medical and health sciences, 0302 clinical medicine, medicine, Fertility preservation, Ovarian reserve, GnRH agonist, 030219 obstetrics & reproductive medicine, business.industry, Oocyte cryopreservation, 030104 developmental biology, medicine.anatomical_structure, Reproductive Medicine, Original Article, business, hormones, hormone substitutes, and hormone antagonists, Hormone
Abstract

Objective: The aim of this study was to determine whether co-administration of a gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin (hCG) for final oocyte maturation improved mature oocyte cryopreservation outcomes in young women with decreased ovarian reserve (DOR) compared with hCG alone.Methods: Between January 2016 and August 2019, controlled ovarian stimulation (COS) cycles in women (aged ≤35 years, anti-Müllerian hormone [AMH]

Published
2020

49. Efficacy and safety of newly developed ganirelix acetate in infertile women for assisted reproductive technology: a prospective, randomised, controlled study

Author

Han, E. Jung, Lyu, Sang Woo, Kwak, In Pyung, Kwon, Hwang, Choi, Dong Hee, Kim, Jin Young, Park, Han Moie, Kim, Ji Won, Chang, Eun Mi, Lee, Hee Jun, Kim, Min Kyung, Lee, Hye Nam, Kim, Jeong Yun, La Park, So, and Lee, Woo Sik

Subjects
Gonadotropin-Releasing Hormone, Hormone Antagonists, Ovulation Induction, Obstetrics and Gynecology, Humans, Female, Fertilization in Vitro, Prospective Studies, Luteinizing Hormone, Chorionic Gonadotropin, Infertility, Female, hormones, hormone substitutes, and hormone antagonists
Abstract

This study aimed to investigate the efficacy of Ganilever pre-filled syringe (PFS), a newly developed ganirelix acetate, for the inhibition of premature luteinising hormone (LH) surge in in vitro fertilisation (IVF). A prospective randomised controlled study was conducted (NCT03051087). A total of 236 women (Ganilever group: 114, Orgalutran group: 122) were finally analysed. The patients with LH of >10 mIU/mL on the day of human chorionic gonadotropin (hCG) injection were 0 (0.0%) and 3 (2.5%) in the Ganilever and Orgalutran groups, respectively (p= .25). The number of retrieved oocytes from two groups did not show any significant difference (12.0 ± 6.4 vs. 11.8 ± 6.3, p= .73). Furthermore, the two groups did not show significant differences in the number of good-quality oocytes and embryo, and the rate of fertilisation. Similar safety profiles were also observed. In conclusion, Ganilever PFS showed comparable IVF outcomes and safety profile in IVF, as compared to the Orgalutran. Impact StatementWhat is already known on this subject? Premature LH surge during controlled ovarian stimulation results in the induction of luteinisation of the immature follicles. Thus, gonadotrophin-releasing hormone (GnRH) antagonist protocol was suggested as an option for suppression of premature LH surge. Currently, one of GnRH antagonists being widely used is ganirelix acetate (Orgalutran®; Organon, Oss, The Netherlands). Ganilever pre-filled syringe (PFS) is a newly developed GnRH antagonist containing ganirelix acetate as an active ingredient.What do the results of this study add? Our study demonstrated that Ganilever PFS showed comparable IVF outcomes and patient safety profile in infertile women undergoing in IVF-ET, as compared to the Orgalutran.What are the implications of these findings for clinical practice and/or further research? The results of our study will provide another available GnRH antagonist to be used in patients with IVF. What is already known on this subject? Premature LH surge during controlled ovarian stimulation results in the induction of luteinisation of the immature follicles. Thus, gonadotrophin-releasing hormone (GnRH) antagonist protocol was suggested as an option for suppression of premature LH surge. Currently, one of GnRH antagonists being widely used is ganirelix acetate (Orgalutran®; Organon, Oss, The Netherlands). Ganilever pre-filled syringe (PFS) is a newly developed GnRH antagonist containing ganirelix acetate as an active ingredient. What do the results of this study add? Our study demonstrated that Ganilever PFS showed comparable IVF outcomes and patient safety profile in infertile women undergoing in IVF-ET, as compared to the Orgalutran. What are the implications of these findings for clinical practice and/or further research? The results of our study will provide another available GnRH antagonist to be used in patients with IVF.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results